nach oben

Drug Safety

Erschienen in:

01.01.2003 | Leading Article

Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class

Are They Clinically Relevant?

verfasst von: Dr Jennifer Martin, Henry Krum

Erschienen in: Drug Safety | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Abstract

The present review outlines the clinical relevance of pharmacokinetic drug interactions within the HMG-CoA reductase inhibitor class. These interactions can result in markedly increased or decreased plasma concentrations of some drugs within this class. However, the relationship between altered plasma concentrations and adverse effects or toxicity may not be linear. It is likely that other variables affect this concentration-effect relationship including: rapid changes in the concentration, concomitant lipid-lowering therapy or host genetic factors that code for different forms or amounts of metabolising enzymes and drug receptors.

It is not currently possible to predict which patients will manifest clinically important drug-drug interactions, nor what concentration of an HMG-CoA reductase inhibitor will cause rhabdomyolysis. Thus, until prescribers have better scientific information from which to develop a ‘therapeutic range’ for each agent, caution should be exercised. In particular, patients taking a CYP3A4-metabolised agent, e.g. atorvastatin, simvastatin and lovastatin, should not be started on a CYP3A4 inhibitor or inducer without close monitoring.

Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme a reductase inhibitors. Arch Intern Med 2000; 160: 2273–80PubMedCrossRef

McCormick AD, Butters CJ. ZD4522: an HMG-CoA reductase inhibitor free of metabolically medicated drug interactions: metabolic studies in human in vitro systems. 29th Annual Meeting of the American College of Clinical Pharmacology; 2000 Sep 17-19; Chicago (IL), 2002

Azie N, Brater BC, Becker P, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64(4): 369–77PubMedCrossRef

Yeo KR. Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51(5): 461–70PubMedCrossRef

Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64(2): 177–82PubMedCrossRef

Kantola T, Neuvonen P. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58–65PubMedCrossRef

Neuvonen P, Kantola T, Kivisto K. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63(3): 332–41PubMedCrossRef

Kivisto K, Kantola T, Neuvonen P. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49–53PubMedCrossRef

Kantola T, Neuvonen P. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 387–402CrossRef

10.

Lilja J, Neuvonen P. Grapefruit juice - simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477–83PubMedCrossRef

11.

Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibafredil. Lancet 1998; 351: 1929–30PubMedCrossRef

12.

Kent J. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2001; 355(9207): 911–8CrossRef

13.

Martin J, Fay M. Cytochrome P450 drug interactions: are they clinically relevant? Australian Prescriber 2001; 24(1): 10–2

14.

Davidson M. Statin drug interactions in the elderly. J Cardiovasc Pharmacol Ther 2001; 6(3): 219–29PubMedCrossRef

15.

Sugimoto K, Ohmori M, Tsuruka S, et al. Different effects of St John’s Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70(6): 518–24PubMedCrossRef

16.

Hsyu P H, Schultz-Smith M, Lillibrisge J, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45(12): 3445–50PubMedCrossRef

17.

Ruschitzka F, Meier P, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort [letter]. Lancet 2000; 35 (9203): 548–9CrossRef

18.

Lees R. Rhabdomyolysis from the co-administration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 644–5CrossRef

19.

Beaird S. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40: 637–44

20.

Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 1996; 132: 1254–5PubMedCrossRef

21.

Ahmad S. Diltiazem myopathy. Am Heart J 1993; 126: 1494–5PubMedCrossRef

22.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7–22

23.

Rodriguez JA, Paniagua MJ, Crespo-Leiro MG, et al. Rhabdomyolysis with HMG Co-A reductase inhibitors after heart transplant: incidence and prognosis [poster]. Presented at the European Society of Cardiology Congress; 1998 Aug 22-26; Vienna

24.

Keogh A, Macdonald P, Aboyoun C, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529–37PubMedCrossRef

25.

Barclay P, O’Connell P. Clarithromycin drug interactions complicating cyclosporin and simvastatin therapy [letter]. Aust J Hosp Pharm 1996; 26: 180

26.

Corpier C, Jones P, Suki W, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. J Am Med Assoc 1988; 260(2): 239–41CrossRef

27.

Maltz H, Balog D, Cheigh J. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176–9PubMedCrossRef

28.

Muck W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65: 251–61PubMedCrossRef

29.

Regazzi M, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporine A in transplant recipients. Transplant Proc 1993; 25: 2732–4PubMed

30.

Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin but not pravastatin in blood of cyclsporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311–21PubMedCrossRef

31.

Goldberg R, Roth O. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559–64PubMedCrossRef

32.

Gruer P, Vega J, Mercuri M, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811–5PubMedCrossRef

33.

Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis 2002; Suppl.3: 35–40

34.

Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of the 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1–34PubMedCrossRef

35.

Spach D, Clark C, Burke W. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213–5PubMed

36.

Ayanian J, Fuchs C, Stone R. Lovastatin and rhabdomyolysis [letter]. Ann Intern Med 1998; 1009: 682–3

37.

Heerey A, Barry M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000; 169(3): 176–9PubMedCrossRef

38.

Jacobson R, Wang P, Glueck C. Myositis and rhabdomyolysis associated with current use of simvastatin and nefazodone [letter]. JAMA 1997; 277: 296–7PubMedCrossRef

39.

LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 Nov 5; 339 (19): 1349–57

40.

Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 Nov 16; 333(20): 1301–7PubMedCrossRef

41.

Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct 3; 335(14):1001–9PubMedCrossRef

42.

Pfeffer M, Keech A, Cobbe S, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) project. Circulation 2002; 105: 2341–6PubMedCrossRef

43.

Furber C Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiavasc Med 2001; 2: 205–7CrossRef

44.

Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 356–64CrossRef

45.

Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22(6): 441–57PubMedCrossRef

46.

Wen X, Wang J, Backman J, et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29: 1359–61PubMed

47.

Prueksaritanont T, Zhao J, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042–51PubMedCrossRef

48.

Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13–20PubMedCrossRef

Titel: Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class
Are They Clinically Relevant?
verfasst von: Dr Jennifer Martin
Henry Krum
Publikationsdatum: 01.01.2003
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 1/2003
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200326010-00002

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class

Are They Clinically Relevant?

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2003

Aristolochic Acid and ‘Chinese Herbs Nephropathy’

Patients’ Understanding of Risk Associated with Medication Use

Benefits and Risks of Pharmacotherapy for Dysthymia

Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis

Adverse Events Associated with Rofecoxib Therapy